FDA Should Rethink Its Definition Of A High-Risk Device, Say Patient Advocates
This article was originally published in The Gray Sheet
Executive Summary
Patient and consumer groups urged FDA to rethink its current stance on what constitutes a high-risk device at a meeting on the 510(k) program last week.
You may also be interested in...
FDA Panel: Transvaginal Mesh For Prolapse Should Be Class III
Current and future surgical mesh devices for pelvic organ prolapse repair would require PMA submissions under a recommendation last week by FDA’s Obstetrics and Gynecology Devices panel.
Institute Of Medicine On 510(k) Review Program: Dump It
The Institute of Medicine committee charged with reviewing FDA's 510(k) device pre-market review program is urging the agency to ditch the 35-year-old program and start fresh.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”